Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes

Publisher： Karger

E-ISSN： 1423-0259|55|2|84-90

ISSN： 0030-3747

Source： Ophthalmic Research, Vol.55, Iss.2, 2016-0, pp. : 84-90

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 237, Iss. 2, 2017-02 ,pp. : 105-110

Karger

Access to resources Recommend Favorite

A Case of Sustained Intraocular Pressure Elevation after Multiple Intravitreal Injection of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration

By  

Case Reports in Ophthalmology, Vol. 7, Iss. 1, 2016-04 ,pp. : 230-236

Karger

Access to resources Recommend Favorite

Comparison of pro re nata versus Bimonthly Injection of Intravitreal Aflibercept for Typical Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 238, Iss. 1-2, 2017-04 ,pp. : 17-22

Karger

Access to resources Recommend Favorite

Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 235, Iss. 1, 2016-0 ,pp. : 42-48

Karger

Access to resources Recommend Favorite

Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 370-375

Karger

Access to resources Recommend Favorite